million
peopl
worldwid
persist
infect
hepat
b
viru
hbv
risk
develop
chronic
liver
diseas
cirrhosi
hepatocellular
carcinoma
hcc
effect
afford
therapi
achiev
sustain
suppress
hbv
replic
remiss
liver
diseas
urgent
need
pegyl
interferonalpha
ifna
recommend
treatment
chronic
hepat
b
chb
current
consensu
guidelin
mani
countri
compar
convent
recombin
ifna
howev
pegyl
ifna
alon
combin
nucleosid
analogu
significantli
increas
rate
sustain
respons
nucleo
ide
analogu
entecavir
tenofovir
suppress
hbv
replic
result
improv
liver
architectur
howev
agent
erad
hbv
genom
liver
may
limit
develop
increasingli
select
drugresist
mutant
prolong
use
therapi
addit
antivir
drug
target
step
viral
life
cycl
combin
immunomodulatori
option
might
benefici
effect
acut
infect
adult
resolv
clinic
symptom
maintain
lifelong
protect
immun
mount
vigor
multispecif
immun
respons
hbv
protein
contrast
patient
chronic
hepat
b
tend
delay
transient
narrowli
focus
cell
respons
patient
spontan
recov
hbv
infect
might
experi
reactiv
hbv
immunosuppress
treatment
thu
specif
immun
respons
hbv
remain
crucial
longterm
control
hbv
infect
even
resolut
acut
infect
chronic
infect
patient
immunostimulatori
immunomodulatori
strategi
boost
broaden
weak
virusspecif
cell
respons
propos
reach
effect
control
viral
infect
sinc
year
numer
clinic
trial
exploit
convent
prophylact
vaccin
base
hepat
b
surfac
antigen
hbsag
therapeut
vaccin
tabl
studi
demonstr
reduct
viremia
seroconvers
hepat
b
e
antigen
hbeag
antihb
hbvspecif
cell
respons
patient
vaccin
howev
antivir
effect
transient
lead
effect
control
hbv
sophist
therapeut
vaccin
base
hbsag
complex
human
antihb
propos
group
wen
et
al
immunogen
complex
ic
stimul
robust
cell
respons
increas
uptak
hbsag
fc
receptor
antigenpres
cell
apc
therefor
enhanc
hbsag
process
present
demonstr
vaccin
administ
hbeagposit
patient
led
decreas
hbv
dna
serum
hbeag
seroconvers
subject
phase
ii
b
clinic
trial
hbeag
seroconvers
observ
treat
patient
moreov
moder
decreas
serum
hbv
dna
hbsag
level
observ
treatment
recent
larg
phase
iii
clinic
trial
inject
ic
complex
fail
show
therapeut
efficaci
compar
placebo
control
inject
alum
overstimul
icbas
vaccin
increas
decreas
efficaci
therapeut
vaccin
result
underlin
appropri
immun
protocol
crucial
efficaci
therapeut
vaccin
dna
vaccin
use
plasmid
express
viral
protein
gain
popular
given
abil
induc
strong
cellular
humor
immun
respons
sever
phase
clinic
studi
investig
therapeut
efficaci
plasmid
dna
vaccin
express
hbsag
chronic
hbv
carrier
studi
show
evid
safeti
hbv
dna
vaccin
detail
see
cell
respons
restor
activ
low
level
furthermor
dna
vaccin
express
hbsag
result
signific
suppress
viremia
chronic
carrier
hbv
result
studi
conclud
therapeut
vaccin
alon
suffici
achiev
control
hbv
high
load
viru
particl
larg
amount
hbsag
liver
peripher
blood
may
respons
immun
toler
statu
patient
therefor
pretreat
nucleo
ide
analogu
propos
achiev
better
cell
respons
subsequ
therapeut
efficaci
administr
dna
vaccin
recent
result
trial
combin
therapi
publish
larg
doubleblind
studi
patient
treat
effect
nucleo
ide
analogu
median
year
result
undetect
level
hbv
dna
thereaft
random
two
group
one
receiv
five
intramuscular
inject
dna
vaccin
express
hbsag
one
receiv
placebo
nucleo
ide
analogu
stop
although
combin
therapi
fairli
well
toler
hbv
dna
vaccin
decreas
risk
relaps
hbvtreat
patient
restor
antihbv
immun
respons
despit
effect
viral
suppress
analogu
studi
korea
patient
randomli
receiv
either
adefovir
adv
alon
adv
combin
hbsagexpress
dna
vaccin
therapeut
vaccin
safe
toler
chb
patient
vaccineinduc
hbvspecif
cell
respons
hbeag
seroconvers
weaker
korean
patient
caucasian
patient
asian
patient
gener
infect
via
vertic
transmiss
may
higher
level
immun
toler
caucasian
usual
infect
later
life
improv
vaccin
break
immun
toler
may
need
develop
effect
therapeut
hbv
dna
vaccin
aim
studi
vietnam
evalu
viral
suppress
follow
combin
treatment
new
vaccin
contain
three
envelop
protein
hbv
lamivudin
chb
patient
enhanc
suppress
viremia
combin
group
revers
discontinu
vaccin
treatment
suggest
booster
dose
requir
sustain
viral
respons
antihb
detect
vaccin
recipi
three
patient
demonstr
hbsag
loss
indic
vaccineinduc
antihb
unabl
complet
neutral
hbsag
serum
eastern
woodchuck
marmota
monax
natur
infect
woodchuck
hepat
viru
whv
discov
whv
found
close
relat
hepat
b
viru
hbv
classifi
second
member
genu
orthohepadnaviru
famili
hepadnavirida
contrast
hbvassoci
hcc
patient
without
prefer
integr
site
hbv
dna
frequent
integr
whv
genom
close
nmyc
cmyc
gene
observ
woodchuck
develop
hcc
infect
woodchuck
whv
shown
endem
midatlant
state
usa
wherea
state
new
york
new
england
woodchuck
rare
infect
whv
recent
chines
marmot
marmota
himalayana
found
suscept
whv
infect
fig
find
indic
himalayana
phylogenet
close
relat
monax
therefor
chines
marmota
speci
explor
model
hepadnavir
infect
prevent
infect
futur
new
therapi
molecular
character
whv
experiment
infect
woodchuck
whv
great
valu
model
sever
aspect
hepadnavir
infect
human
eg
natur
cours
infect
immunopathogenesi
includ
innat
adapt
immun
respons
host
viral
factor
associ
develop
chronic
medic
point
view
woodchuck
model
use
develop
new
strategi
prevent
infect
postexposur
prophylaxi
hepat
b
therapi
chronic
hepadnavir
infect
includ
nucleosid
analogu
nonnucleosid
analogu
therapeut
vaccin
review
genetherapeut
approach
treatment
hcc
liver
transplant
recent
establish
woodchuck
studi
earli
event
reinfect
adopt
immun
transfer
late
signific
progress
made
model
demonstr
cellular
immun
respons
need
elimin
viru
hepatocyt
least
control
viral
replic
review
focus
character
woodchuck
gene
relat
innat
adapt
respons
recent
develop
new
tool
determin
virusspecif
cell
respons
therapeut
vaccin
final
immunostimulatori
immunomodulatori
approach
treat
chronic
whv
infect
new
find
preclin
model
help
develop
new
strategi
treat
chronic
hbv
infect
patient
recent
year
mani
effort
devot
clone
character
compon
woodchuck
immun
system
number
immun
functionrel
gene
includ
cytokin
receptor
immun
cell
surfac
marker
immun
functionrel
protein
clone
character
far
import
woodchuck
cytokin
receptor
gmcsf
lymphotoxin
lt
clone
test
biolog
activ
patient
ifn
use
treatment
chb
mani
year
therefor
ifn
system
also
character
woodchuck
woodchuck
shown
reduc
whv
surfac
antigen
express
dosedepend
fashion
whvinfect
woodchuck
hepatocyt
woodchuck
system
express
peripher
blood
lymphocyt
pbl
whvinfect
woodchuck
also
studi
woodchuck
gene
could
classifi
ten
subtyp
three
pseudotyp
poli
c
stimul
woodchuck
pbl
could
induc
subtyp
one
four
five
product
indic
select
express
woodchuck
subtyp
moreov
pbl
chronic
whvinfect
woodchuck
show
reduc
abil
produc
woodchuck
ifn
stimul
poli
c
complet
partial
sequenc
type
ifn
receptor
ifnar
woodchuck
also
obtain
analys
fan
et
al
stimul
significantli
upregul
express
primari
woodchuck
hepatocyt
decreas
express
observ
woodchuck
chronic
infect
whv
data
essenti
studi
type
ifnrel
innat
immun
therapi
hepadnavir
infect
woodchuck
model
pleiotrop
cytokin
act
varieti
immun
cell
cell
surfac
receptor
suggest
resuscit
antivir
immun
interf
pathway
increas
product
observ
patient
chb
hint
blockad
might
becom
feasibl
therapeut
approach
chb
recent
jiang
et
al
success
clone
woodchuck
gener
antibodi
molecul
blockad
woodchuck
enhanc
prolifer
degranul
specif
cell
chronic
whvinfect
woodchuck
vitro
work
provid
basi
potenti
therapeut
approach
chronic
hbv
infect
import
woodchuck
immun
cell
surfac
molecul
clone
far
divid
two
categori
base
function
molecul
involv
innat
immun
molecul
involv
adapt
immun
tolllik
receptor
tlr
class
molecul
play
key
role
innat
immun
system
recent
progress
field
reveal
signific
interact
tlr
system
pathogen
chronic
viral
infect
far
success
clone
woodchuck
recent
studi
zhang
et
al
show
ligand
induc
activ
differ
arm
mapk
signal
pathway
product
proinflammatori
cytokin
woodchuck
hepatocyt
innat
immun
respons
reduc
replic
gene
express
hbv
cell
whv
primari
woodchuck
hepatocyt
see
also
articl
zhang
lu
issu
chronic
whv
carrier
woodchuck
model
rel
low
level
express
found
pbmc
liver
tissu
express
pbmc
invers
correl
whv
dna
titr
acut
whv
infect
entecavirtr
chronic
whv
carrier
effect
immun
respons
viral
infect
depend
activ
cell
clear
infect
kill
virusinfect
cell
therefor
sequenc
inform
woodchuck
use
determin
kinet
influx
cell
liver
incub
period
acut
chronic
whv
infect
week
two
postinfect
influx
lymphocyt
could
observ
reach
higher
level
prior
recoveri
phase
peak
level
cell
coincid
recoveri
transient
infect
cell
accumul
liver
reach
twothird
total
number
liver
cell
adapt
immun
respons
known
play
import
role
regul
cell
activ
deliv
costimulatori
signal
complet
code
region
woodchuck
cytotox
tlymphocyteassoci
antigen
clone
sequenc
woodchuck
show
similar
human
mous
homologu
respect
accord
deduc
amino
acid
sequenc
woodchuck
higher
similar
correspond
human
mous
molecul
respect
strict
conserv
critic
amino
acid
residu
like
cystein
asparagin
residu
woodchuck
suggest
molecul
may
structur
resembl
human
mous
homologu
hexapeptid
motif
mypppi
suppos
essenti
interact
present
woodchuck
advanc
sequenc
technolog
provid
new
tool
character
gene
woodchuck
immun
system
larg
scale
fletcher
et
al
perform
sequenc
assembl
annot
woodchuck
transcriptom
togeth
gener
custom
woodchuck
microarray
use
new
platform
character
transcript
respons
persist
whv
infect
whvinduc
hcc
liu
et
al
also
perform
de
novo
woodchuck
transcriptom
assembl
use
deep
sequenc
technolog
unpublish
data
help
advanc
technolog
sequenc
inform
import
immun
gene
woodchuck
reveal
shown
upregul
led
specif
nonhepatotox
degrad
nuclear
hbv
cccdna
therefor
futur
clone
character
woodchuck
model
evalu
therapeut
potenti
chb
summari
effort
establish
translat
valu
woodchuck
model
provid
new
insight
character
immun
pathway
may
play
role
persist
hbv
infect
studi
patient
underlin
import
role
hbvspecif
cell
respons
lead
factor
viral
clearanc
mani
year
lack
appropri
method
evalu
antigenspecif
cell
respons
seriou
limit
model
establish
assay
monitor
cellular
immun
respons
woodchuck
great
import
reliabl
evalu
therapeut
immunomodulatori
strategi
treatment
chb
woodchuck
model
develop
adeninebas
prolifer
assay
enabl
detect
thelper
lymphocyt
respons
stimul
woodchuck
pbmc
addit
sever
thelper
epitop
within
whcag
identifi
pbmc
acut
whvinfect
anim
signific
progress
studi
cell
respons
woodchuck
achiev
introduct
flow
cytometr
degranul
assay
enabl
detect
whvspecif
cytotox
cell
ctl
woodchuck
pbmc
splenocyt
sever
studi
demonstr
detect
degranul
marker
suitabl
method
determin
antigenspecif
cytotox
lymphocyt
introduct
immunolog
tool
studi
cell
respons
woodchuck
reveal
signific
similar
pathogenesi
whv
infect
woodchuck
hbv
human
demonstr
acut
selflimit
resolv
whv
infect
correl
robust
multifunct
thelper
cytotox
cell
respons
whv
chronic
carrier
demonstr
weak
virusspecif
cell
respons
viral
protein
tabl
moreov
studi
confirm
effici
cellular
immun
respons
viral
antigen
result
liver
injuri
necessari
viral
clearanc
recent
describ
advanc
character
monitor
woodchuck
immun
system
whv
infect
made
anim
model
particularli
use
develop
immunomodulatori
approach
chb
pioneer
investig
therapeut
vaccin
base
whv
core
surfac
antigen
combin
helper
peptid
name
fi
encompass
amino
acid
fiseaiihvlhsr
sperm
whale
myoglobin
potent
adjuv
like
monophosphoryl
lipid
lead
satisfactori
result
experi
prove
vaccin
could
induc
specif
b
cell
andor
cell
respons
chronic
whv
carrier
howev
alon
suffici
achiev
control
viru
replic
high
load
viru
may
respons
immun
toler
statu
anim
idea
support
boni
et
al
report
cell
respons
hbv
success
restor
patient
treat
lamivudin
addit
quantiti
antigen
particularli
whv
surfac
antigen
whsag
immun
system
expos
induc
differ
degre
function
impair
antivir
cell
physic
cell
delet
combin
therapi
use
lamivudin
serumderiv
whsag
vaccin
show
effect
induct
antiwh
antibodi
reduct
whv
dna
group
evalu
efficaci
combin
therapi
woodchuck
model
combin
lamivudin
treatment
dna
vaccin
three
plasmid
express
whsag
whcag
woodchuck
whsagantiwh
immunogen
complex
vaccin
tripl
combin
led
decreas
whv
viral
load
log
serum
whsag
develop
antiwh
antibodi
nevertheless
effect
sustain
paramet
reach
baselin
level
shortli
withdraw
lamivudin
treatment
addit
vaccin
induc
whvspecif
cell
respons
major
woodchuck
even
anim
exhibit
virolog
respons
later
modifi
protocol
use
potent
antivir
drug
entecavir
etv
increas
number
immun
plasmid
express
whsag
whcag
three
six
lu
et
al
unpublish
result
signific
delay
rebound
viremia
observ
woodchuck
receiv
addit
vaccin
compar
control
treat
etv
anoth
studi
chronic
whv
carrier
receiv
treatment
potent
antivir
drug
clevudin
combin
alumadsorb
whsag
vaccin
combin
treatment
result
signific
sustain
reduct
whv
dna
load
whsag
concentr
treat
anim
compar
vaccin
alon
combin
treatment
induc
robust
antiwh
respons
result
studi
clearli
show
combin
antivir
treatment
vaccin
effect
induc
virusspecif
cell
respons
therapeut
vaccin
alon
nevertheless
efficaci
approach
still
limit
appli
treatment
chb
vaccin
strategi
use
studi
even
abl
boost
function
antivir
cell
respons
significantli
better
induct
whcagspecif
cell
use
potent
vaccin
recombin
viral
vector
may
requir
achiev
sustain
antivir
respons
viral
clearanc
recombin
adenovir
vector
adv
prove
elicit
vigor
sustain
humor
cell
respons
transduc
antigen
adenovir
vector
also
act
natur
adjuv
caus
dc
matur
enhanc
antigen
present
secret
antivir
cytokin
howev
even
singl
immun
recombin
adenovirus
may
induc
immun
predominantli
neutral
antibodi
vector
neg
effect
adenovirusinduc
immun
vaccin
may
overcom
heterolog
primeboost
regimen
particular
subsequ
prime
immun
plasmid
dna
vaccin
follow
booster
vaccin
adv
seem
promis
strategi
dna
boost
regimen
prove
induc
robust
potent
immun
respons
comparison
plasmid
dna
alon
provid
protect
pathogen
challeng
sever
anim
model
infecti
diseas
see
also
articl
e
barn
issu
recent
group
investig
whether
heterolog
primeboost
immun
strategi
use
plasmid
dna
recombin
adenovir
vector
may
improv
efficaci
therapeut
vaccin
chb
woodchuck
model
new
dna
plasmid
pcgwhc
adenovir
serotyp
vector
chimer
display
fibr
show
high
express
level
whcag
construct
increas
antigen
express
achiev
insert
intron
sequenc
express
cassett
vaccin
preliminari
result
show
new
vaccin
abl
induc
strong
sustain
whcagspecif
cell
respons
mice
woodchuck
interestingli
immun
adv
led
rapid
massiv
product
antiwh
antibodi
result
resolut
infect
whv
challeng
dna
boost
immun
strategi
use
therapeut
vaccin
chronic
whv
infect
combin
antivir
treatment
etv
six
chronic
whvinfect
woodchuck
treat
week
etv
start
week
eight
four
six
etvtreat
anim
receiv
subsequ
nine
intramuscular
immun
dna
plasmid
express
whcag
pcgwhc
whsag
pwhsim
whsag
whcagspecif
thelper
cytotox
cell
respons
detect
chronic
carrier
receiv
immun
etv
treat
anim
addit
woodchuck
receiv
combin
therapi
show
prolong
suppress
whv
replic
lower
whsag
level
compar
control
excitingli
two
four
immun
carrier
remain
whv
dna
neg
end
etv
treatment
develop
antiwh
antibodi
data
encourag
demonstr
combin
antivir
vaccin
approach
effici
elicit
sustain
immunolog
control
chronic
hepadnavir
infect
woodchuck
persist
hbv
infect
associ
function
exhaust
virusspecif
cell
defect
virusspecif
cell
one
primari
reason
inabl
host
elimin
persist
pathogen
although
shown
nucleosid
analogu
treatment
induc
recoveri
hbvspecif
ctl
activ
patient
effect
transient
find
consist
data
obtain
woodchuck
model
etv
treatment
alon
induc
either
transient
ctl
respons
respons
therefor
addit
strategi
potent
enhanc
cell
respons
need
enrol
treatment
chb
infect
recent
studi
chronic
viru
infect
model
indic
interact
inhibitori
receptor
program
ligand
play
critic
role
cell
exhaust
chronic
hbv
infect
upregul
virusspecif
cell
observ
restor
cell
function
achiev
block
interact
vitro
recent
therapeut
effect
blockad
also
investig
chronic
hcv
infect
chimpanze
patient
howev
limit
effect
restor
cell
function
observ
studi
use
blockad
recent
clarifi
proport
cell
express
level
virusspecif
cell
strongli
correl
viral
load
plasma
antiretrovir
treatment
result
dramat
declin
plasma
viral
load
coincid
decreas
express
level
virusspecif
cell
line
better
restor
cell
function
upon
vitro
treatment
observ
chronic
hbv
patient
lower
viremia
therefor
combin
therapi
includ
direct
antivir
drug
blockad
reason
strategi
treatment
chronic
hbv
infect
line
find
zhang
et
al
liu
et
al
success
clone
character
woodchuck
system
whv
infect
woodchuck
model
signific
posit
correl
viral
load
express
total
cell
chronic
whv
infect
observ
proport
cell
level
express
cell
significantli
higher
woodchuck
chronic
whv
infect
compar
anim
resolv
importantli
etv
treatment
chronic
carrier
reduct
serum
viral
load
correl
dramat
decreas
level
express
cell
vitro
blockad
woodchuck
pathway
use
rabbit
polyclon
block
antibodi
could
partial
restor
cell
function
whvinfect
woodchuck
moreov
vivo
blockad
pathway
cell
combin
nucleosid
analogu
treatment
dna
vaccin
synergist
enhanc
function
virusspecif
cell
combin
therapi
potent
suppress
whv
replic
lead
sustain
immunolog
control
viral
infect
antiwh
antibodi
develop
complet
viral
clearanc
woodchuck
although
similar
approach
tri
virus
past
lcmv
data
present
may
advanc
hbv
field
new
approach
elimin
viru
rather
suppress
replic
woodchuck
valuabl
preclin
model
develop
new
therapeut
approach
chronic
hepadnavir
infect
even
though
sever
innov
approach
combin
antivir
treatment
nucleosid
analogu
dna
vaccin
protein
vaccin
test
chronic
infect
woodchuck
effect
strategi
limit
strategi
investig
far
often
hamper
weak
cell
respons
observ
immun
suggest
strong
need
altern
strategi
enhanc
cell
function
chronic
hbv
infect
recent
group
publish
two
independ
proofofconcept
studi
show
use
potent
cell
vaccin
blockad
neg
signal
cell
may
lead
resolut
chronic
hepat
b
woodchuck
tabl
data
encourag
implic
feasibl
use
immunotherapeut
strategi
treatment
chronic
hbvinfect
patient
nevertheless
factor
influenc
effect
therapeut
vaccin
remain
investig
notic
satisfactori
therapeut
effect
could
document
studi
use
hbsagbas
prophylact
vaccin
mean
time
evid
support
hbcagspecif
immun
endow
antivir
liverprotect
capac
chb
patient
anim
model
increas
number
avail
vaccin
formul
crucial
question
rais
recent
optim
combin
vaccin
obvious
necessari
test
mutual
influenc
differ
type
vaccin
maxim
effect
avoid
neg
interfer
vaccin
also
question
hbv
infect
lead
defect
immun
respons
hbv
protein
remain
investig
issu
key
ration
design
new
therapeut
approach
figur
summar
idea
potenti
combin
treatment
patient
chronic
hepat
b
presenc
viral
compon
may
main
reason
cell
toler
chronic
hbv
infect
antivir
treatment
nucleosid
analogu
effici
reduc
hbv
replic
releas
new
virion
may
partli
restor
hbvspecif
cell
respons
therebi
allow
success
therapeut
vaccin
howev
hbv
protein
still
produc
transcript
mrna
protein
core
protein
hbv
cccdna
affect
antivir
treatment
even
hbv
dna
disappear
antivir
treatment
hbsag
hbcaghbeag
present
liver
blood
high
level
propos
reduc
hbv
protein
load
small
interf
rna
sirna
lead
sequencespecif
degrad
homolog
mrna
use
rna
interfer
rnai
chemic
synthes
vectorexpress
sirna
mani
clinic
relev
virus
includ
human
immunodefici
viru
hbv
hcv
could
inhibit
vitro
experi
show
whv
transcript
could
degrad
sirna
time
degrad
viral
rna
result
activ
multipl
pathway
host
innat
immun
respons
howev
futur
vivo
studi
requir
demonstr
use
technolog
combin
genesilenc
approach
nucleosid
analogu
may
facilit
stimul
immun
system
therapeut
vaccin
epigenet
regul
provid
altern
interfer
hbv
gene
express
hbv
minichromosom
hepatocyt
complex
control
epigenet
mechan
transcript
activ
could
influenc
methyl
histon
acetyl
mechan
therefor
explor
epigenet
drug
modifi
regulatori
process
may
achiev
effect
suppress
hbv
gene
express
therebi
replac
antivir
treatment
nucleosid
analogu
stimul
innat
immun
respons
may
contribut
control
hbv
infect
special
issu
zhang
lu
provid
review
dedic
role
tlr
system
interferon
interferonstimul
gene
isg
repres
still
import
part
antihbv
treatment
recent
review
aspect
describ
current
progress
pei
et
al
press
recent
antivir
function
isg
studi
exampl
interferoninduc
protein
tetratricopeptid
repeat
cellular
factor
shown
limit
hepat
b
viru
replic
hepatoma
cell
anoth
recent
report
lucifora
et
al
role
apobec
degrad
cccdna
highli
interest
remain
controversi
futur
investig
requir
elucid
function
isg
rel
contribut
control
hbv
infect
explor
gene
antivir
treatment
